Natera spent over a decade making non-invasive prenatal testing mainstream, then figured out the same cell-free DNA technology could monitor cancer recurrence — and that turned out to be worth more. Signatera is now used by oncologists at major cancer centers to detect relapse earlier than any scan can. The prenatal business was the proof of concept. The cancer business is the company.
Founded
2004
HQ
Austin, TX
Total Raised
Public (NASDAQ: NTRA)
Founder
Matt Rabinowitz, Jonathan Sheena
Status
Public (NASDAQ: NTRA) — growing rapidly, oncology becoming the dominant revenue driver
Website
natera.comTHE ORIGIN STORY
Matt Rabinowitz was a communications engineer who got interested in non-invasive prenatal testing (NIPT) — using fetal DNA circulating in a mother's bloodstream to test for chromosomal abnormalities like Down syndrome. In 2004, this was scientifically plausible but technically challenging.
He and Jonathan Sheena spent years developing the cell-free DNA analysis platform before commercializing. When NIPT began replacing amniocentesis (a more invasive and risky procedure) as the prenatal screening standard, Natera was positioned as one of the leaders.
It went public in 2015.
WHAT THEY ACTUALLY DO
Natera charges for genetic tests. Most tests are sent to doctors as part of routine prenatal care or oncology workups — the doctor orders the test, Natera bills insurance.
The company also sells directly to oncologists for cancer monitoring (Signatera circulating tumor DNA test). Revenue is a mix of insurance reimbursement, patient co-pays, and hospital/clinic contracts.
THE PRODUCTS
Panorama (NIPT prenatal screening), Horizon (carrier screening), Signatera (personalized cancer monitoring ctDNA test), Prospera (transplant rejection testing)
HOW THEY GREW
Natera diversified beyond prenatal into oncology. Signatera — a personalized tumor DNA test that detects cancer residual disease and recurrence earlier than imaging — became one of the fastest-growing molecular oncology tests in the US.
Partnerships with major cancer centers and pharmaceutical companies for clinical trials provided both revenue and validation. Expansion into organ health (transplant monitoring) added a third market vertical.
THE HARD PART
Insurance reimbursement for genetic tests is a perpetual fight. Natera has had to lobby, litigate, and negotiate coverage for its tests — particularly for expanded carrier screening (Horizon) and cancer monitoring (Signatera).
The oncology pivot, while promising, requires convincing oncologists to change monitoring protocols and use a relatively new liquid biopsy test. And competition is intense: Exact Sciences, Foundation Medicine, and Guardant Health are all fighting for the same physician prescribing behavior.
WHO BACKED THEM
Sequoia Capital, TPG, Lightspeed Venture Partners, Series A–E institutional investors
Related Profiles
Head-to-Head
Compare Natera vs another company.